Federal IDR: A Lifeline for Critical Access Hospitals

The Subsidy Is a Residual, Not a Price

The connection between arbitration and hospital finance runs through a line item that grows every year and belongs to no one: the subsidy the hospital writes to the emergency medicine group, the anesthesia group, the radiologists, the hospitalists. It is reviewed at contract renewal, negotiated against a staffing model, and defended or attacked on clinician compensation benchmarks. That framing is incomplete, and the incompleteness is expensive.

The subsidy is not a price the hospital pays for physicians. It is a residual — what is left after commercial payers, Medicare and Medicaid have paid the professional claims. Two variables determine it: what the group costs to operate, and what the group collects. Most hospitals negotiate hard on the first and have almost no visibility into the second. They are managing one side of a two-sided equation, and the side they cannot see is controlled by the same payers with whom the hospital negotiates its own facility rates.

Hospital-based specialties share a feature that distinguishes them from every other physician relationship a hospital has: the group controls neither its demand, nor its payer mix, nor its site of service. An emergency medicine group cannot decline the patient, select the payer, or move the encounter to a better-reimbursed setting. Its cost is set by a coverage requirement — the department is staffed to a schedule, not to a volume — while its revenue is set by whoever walks through the door and whatever that patient’s plan pays. When collections fall short of the cost of maintaining the schedule, the party that requires the coverage funds the gap. That is the entire origin of the subsidy.

Two features make this more than an arithmetic exercise. The first is gearing: because collections are large relative to the subsidy, modest movements in reimbursement produce large movements in the subsidy — a 10% collections improvement reduces it by 17% in the illustration above. The second is that the effect recurs. A one-time $250,000 expense reduction happens once. A rate improvement embedded in a multi-year agreement recurs every year of the term and compounds against the escalators.

So the diagnostic question is rarely asked, and it is the one that matters: of the subsidy we fund, how much reflects the genuine cost of coverage, and how much reflects commercial reimbursement that is below market? A hospital that cannot answer it is negotiating in the dark on both sides of the table.

Why the Squeeze Is Sharper in a Critical Access Hospital

The structural problem is universal. Its severity is not — it scales inversely with volume, which is why rural hospitals, critical access hospitals and smaller community hospitals experience it most acutely. The designation exists precisely because these facilities serve communities where the alternative is no hospital at all.

The economics of standby coverage do not scale down. An emergency department seeing 8,000 visits a year and one seeing 40,000 must both be covered every hour of the year. Critical access hospitals have real latitude in how that coverage is staffed — a physician need not be on site at all times, and qualifying clinicians may respond within defined timeframes — but latitude in staffing model is not proportionality in cost. Covering the low-volume department does not cost one-fifth of the high-volume one, because coverage is bought in shifts and call obligations, not in encounters. The same applies to anesthesia call, overnight radiology and hospitalist coverage.

Here a distinction matters, and it is the one most often collapsed. Medicare pays critical access hospitals for facility services on a cost basis rather than under the prospective payment system. That protection is real, and it is frequently cited as the reason CAHs are insulated. But it applies to the facility. The professional services billed by the physicians who staff the emergency department, administer the anesthetic, or read the study are billed separately and paid on a fee schedule. A CAH may elect optional billing for the professional services of clinicians who reassign their billing rights, which carries an enhanced fee schedule rate; that election helps at the margin, but it is not cost-based. And commercial payers — which are where the cross-subsidy has to come from — do not reimburse critical access hospitals on a cost basis at all, for either component.

So the CAH sits in a particular squeeze. Its facility economics are partially protected on the Medicare side; its professional economics are largely unprotected on any side. Its payer mix is weighted toward Medicare and Medicaid, so the commercial book that has to carry the cross-subsidy is small. And its leverage with commercial payers is limited by the very thing that makes it essential: one hospital, one market, a modest covered-lives footprint.

What the Federal IDR Record Actually Shows

Federal arbitration was built for the exception. It now runs at industrial scale, and the record is large enough to be economically meaningful rather than anecdotal.

Dispute volume has more than tripled in two years — arbitration is no longer a marginal channel in hospital-based professional reimbursement. Calendar 2025 produced roughly 2.56 million initiated disputes, about 75% more than calendar 2024 — both figures calculated from the published half-year totals, which the Departments do not aggregate. Certified IDR entities rendered 1,145,039 payment determinations in the second half of 2025 alone and closed more disputes than were initiated. As of the end of 2025, 92% of all disputes ever submitted had been resolved, and 62% of determinations in the period were rendered within 30 business days, up from 37% six months earlier. The system is no longer slow, no longer marginal, and no longer experimental. It is infrastructure.

Other categories ran higher still — surgery at roughly 1,449% and 1,503% of QPA across only about 1,900 decisions, and neurology and neuromuscular procedures at 2,394% and 2,585% across more than 66,000. Health plans and issuers prevailed in roughly 14% of determinations.

Three implications follow for a hospital that subsidizes a hospital-based group. First, the QPA is not a market rate. It is a plan-calculated median — the plan’s median contracted rate for the service in the geographic region, benchmarked to 2019 and indexed forward — that arbitrators declined to adopt in the large majority of contested cases. Plans anchored their offers to it; providers anchored theirs to prior out-of-network payments and prior in-network rates; arbitrators chose the provider’s number roughly six times out of seven.

Second, an in-network rate sitting at or near the QPA is a rate the payer set and no one tested. That is worth stating carefully, because the IDR population is self-selected: disputes are filed precisely where the filer expects to beat the QPA. The median award is a directional benchmark for testing a contracted rate, not an estimate of what any given contract should pay. Used that way it is the most useful independent reference point that exists for hospital-based professional services — and it lands well above where most of these contracts sit.

Third — the point rural executives should sit with — the parties claiming this value are overwhelmingly large and organized. The top three initiating parties in the second half of 2025 (HaloMD, TeamHealth and SCP Health) accounted for approximately 38% of filings, and the top ten for approximately 66%. A community or critical access hospital and its hospital-based group are eligible for the same process, against the same payers, under the same statute — and in most cases are not using it. The value does not disappear. It accrues to the payer, and the hospital funds the difference through the subsidy line.

Leverage First: The Alternative Is How You Get a Stable Agreement

The objective has not changed. It is a stable, sustainable, multi-year in-network agreement — for the hospital, for the physician group, and for the patients who should never see a balance bill. What changed is that rural and critical access hospitals can now credibly obtain one.

Leverage in payer negotiation has always come from the same place: a credible alternative. Large systems have it through market share and network adequacy. A single critical access hospital has neither. Before the No Surprises Act, its practical alternative to an inadequate professional rate was to accept the inadequate rate and absorb the difference through the subsidy. There was no third option. Federal IDR created one, and its economics favor the provider. That alternative exists whether or not a hospital ever files — but payers have priced it precisely and most hospitals have not priced it at all.

And it runs in both directions. A payer that declines to negotiate a sustainable rate does not make the claims disappear; it routes them into a process with a statutory clock, mandatory fees for both parties, and an outcome record that favored providers in roughly 85% of second-half 2025 determinations and exceeded the payer’s own benchmark in roughly 87%. Arbitration is the expensive, slow, statutorily fixed default for any payer that will not come to the table — which is precisely why most of this should be resolvable at it. Facilities are acting on that: health care facilities and their representatives initiated 24% of federal IDR disputes in the second half of 2025, up from 19% six months earlier.

The Work Runs on Two Tracks

Track One is the negotiation, and in most engagements it is where the matter ends — because a specific, data-supported ask on a defined book of professional claims is a different conversation from a general request for more money.

If a material gap remains, Track Two prices the alternative. It does two jobs at once: it prices Track One, because a hospital that can answer “what happens to us economically if we cannot reach an acceptable agreement with this payer?” has an answer to the only question that governs a negotiation — and it is the operating plan if the payer declines.

Track Two is what makes Track One work. A payer that will not reach a sustainable rate does not avoid the economics — it selects into arbitration.

For a critical access hospital, Track Two carries one constraint worth naming plainly. Low volume cuts both ways: it is why the subsidy exists, and it is why per-dispute fees and evidentiary work are harder to absorb. The practical routes are batching eligible claims into economically rational groups, concentrating on the one or two payers driving most of the subsidy, and building the capability alongside the physician group or a partner with the volume to carry it. That is an execution question, not a reason to forgo the leverage. For a hospital with no other source of it, declining to price the alternative is a decision to accept the payer’s number indefinitely — and to keep funding the difference through the subsidy line.

Five Questions for Hospital CFOs and Managed Care Leaders

It Ends in Whether the Emergency Department Stays Open.

What makes this difficult is not the concept. It is that the required information sits in three organizations that rarely exchange it: the hospital holds the subsidy agreements, the physician group holds the professional claims and remittance data, and the payer holds the fee schedules and the QPA methodology. An integrated strategy assembles that picture and acts on it — renegotiation first, with IDR capability built selectively where eligibility and economics support it.

The through-line is straightforward: better payer reimbursement produces stronger physician-group economics, which produces a lower required hospital subsidy, which produces more sustainable hospital-based coverage. For a rural hospital, that last term is not a financial abstraction. The subsidy is not just a budget line — it is the mechanism by which a community keeps its emergency department, and getting the payer side of that equation right is one of the few levers that does not require cutting coverage.